Spyros Papapetropoulos - 16 Apr 2025 Form 4 Insider Report for Neuphoria Therapeutics Inc. (NEUP)

Role: President and CEO, Director
Signature: /s/ Elaine Wangsawidjaja, Attorney-in-Fact for Spyros Papapetropoulos
Issuer symbol: NEUP
Transactions as of: 16 Apr 2025
Net transactions value: +$1,393,200
Form type: 4
Filing time: 18 Apr 2025, 08:04:03 UTC
Previous filing: 08 Jul 2024
Next filing: 05 Jun 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NEUP	Employee Stock Option (Right-to-Buy)	Award	$1,393,200	+270,000	+2155%	$5.16	282,529	16 Apr 2025	Common Stock	270,000	$5.16	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested.